Pernix Therapeutics to Report Third Quarter 2012 Financial Results on November 14, 2012
Pernix Therapeutics Holdings, Inc.Joseph T. Schepers, 800-793-2145 ext. 3002Director, Investor Relations
Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX), a specialty pharmaceutical company, today announced that it will release its third quarter 2012 financial results before the U.S. stock market opens on Wednesday, November 14, 2012 and has scheduled a conference call at 9:00 am EST that day to discuss the financial results.
The conference call will feature remarks by Cooper Collins, Chief Executive Officer, and David Becker, Chief Financial Officer. To participate in the conference call, please dial (888) 364-3109 (domestic) or (719) 325-2432 (international). Participants can reference the passcode 9218466. Please dial in approximately 5 minutes prior to the call.
The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, . Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast.
A replay of the conference call will be available through November 21, 2012, at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for the replay is 9218466. An online archive of the webcast will be available on the Company's website for 30 days following the call.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded and generic products. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiary, Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing, LLC, doing business as Great Southern Laboratories, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. A product candidate utilizing cough-related intellectual property is in development for the U.S. OTC market. Founded in 1996, the Company is based in The Woodlands, TX.
Additional information about Pernix is available on the Company’s website located at